Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study

Cancer Treat Rep. 1986 Feb;70(2):271-4.


Thirty-four patients with advanced or recurrent mixed mesodermal sarcoma of the uterus were entered in a study of single-agent cisplatin as second-line chemotherapy at a dose of 50 mg/m2 iv every 3 weeks. Twenty-eight of the 34 patients had mixed mesodermal sarcomas and measurable disease and had received one or more courses of the drug. Of these patients, five (18%) had objective response to therapy. Two patients who developed clinical complete response had long progression-free intervals (14 and 16 months) and remained alive at 21 and 36 months after initiation of therapy. Adverse effects were those described in a number of series employing cisplatin and were tolerable. Cisplatin thus appears to have definite activity as a second-line agent in the treatment of mixed mesodermal sarcomas of the uterus.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Nausea / chemically induced
  • Thrombocytopenia / chemically induced
  • Uterine Neoplasms / drug therapy*
  • Vomiting / chemically induced


  • Cisplatin